← Patent-cliff monitor Loss of exclusivity February 2036 latest FDA-listed patent expiry
Drug detail Brand name ZERBAXA Active ingredient CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM Strength EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL Dosage form POWDER Route INTRAVENOUS Modality Small molecule FDA approval December 2014 Marketing status RX
Listed patents Patent Expires Type 10125149*PED February 2036 — 10125149 August 2035 product 10376496*PED March 2035 — 10933053*PED March 2035 — 8906898*PED November 2034 — 10420841*PED September 2034 — 9872906*PED September 2034 — 11278622*PED September 2034 — 8968753*PED September 2034 — 9320740*PED September 2034 — 10933053 September 2034 use U-4545 10376496 September 2034 use U-4549 8906898 May 2034 substance, product 9320740 March 2034 product 8968753 March 2034 use U-4547 10420841 March 2034 use U-4547 11278622 March 2034 use U-4543 9872906 March 2034 product 9724353*PED March 2033 — 10028963*PED March 2033 — 10028963 September 2032 use U-4543 9724353 September 2032 use U-4543 7129232*PED November 2028 — 7129232 May 2028 substance, product
Regulatory exclusivity Code Expires PED November 2029 NPP May 2029
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.